Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06834035Phase 1Recruiting

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Role: collaborator

NCT06731933Phase 2Recruiting

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

Role: collaborator

NCT05843994Active Not Recruiting

Artificial Intelligence Patient App for RDEB SCCs

Role: collaborator

NCT03836001Phase 2Completed

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Role: collaborator

NCT02654483Phase 2Completed

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Role: collaborator

All 5 trials loaded